Next Article in Journal
Targeted Polymer-Based Probes for Fluorescence Guided Visualization and Potential Surgery of EGFR-Positive Head-and-Neck Tumors
Previous Article in Journal
Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy
Previous Article in Special Issue
The Role of Nanovaccine in Cross-Presentation of Antigen-Presenting Cells for the Activation of CD8+ T Cell Responses
Open AccessReview

Engineered Nanodelivery Systems to Improve DNA Vaccine Technologies

Nanotechnology Engineering Program, University of Waterloo, Waterloo, ON N2L 3G1, Canada
Department of Chemical and Life Sciences Engineering, Virginia Commonwealth University, Richmond, VA 23284, USA
Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
Department of Chemical, Biological and Bioengineering, North Carolina A&T State University, Greensboro, NC 27411, USA
Department of Genetic Engineering and Biotechnology, Faculty of Biological Sciences, University of Chittagong, Chittagong 4331, Bangladesh
Department of Pharmaceutical Sciences, University of Texas El Paso, El Paso, TX 79968, USA
Department of Agricultural Biotechnology and Research Institute of Agriculture and Technology, Seoul National University, Gwanak-gu, Seoul 08826, Korea
Immuno-Oncology Division, Immunomic Therapeutics, Inc., Rockville, MD 20850, USA
Authors to whom correspondence should be addressed.
Present Address: In Vivo Pharmacology Division, Precigen Inc., Germantown, MD 20876, USA.
Pharmaceutics 2020, 12(1), 30;
Received: 30 October 2019 / Revised: 16 December 2019 / Accepted: 21 December 2019 / Published: 1 January 2020
(This article belongs to the Special Issue Nanoparticles to Improve the Efficacy of Vaccines)
DNA vaccines offer a flexible and versatile platform to treat innumerable diseases due to the ease of manipulating vaccine targets simply by altering the gene sequences encoded in the plasmid DNA delivered. The DNA vaccines elicit potent humoral and cell-mediated responses and provide a promising method for treating rapidly mutating and evasive diseases such as cancer and human immunodeficiency viruses. Although this vaccine technology has been available for decades, there is no DNA vaccine that has been used in bed-side application to date. The main challenge that hinders the progress of DNA vaccines and limits their clinical application is the delivery hurdles to targeted immune cells, which obstructs the stimulation of robust antigen-specific immune responses in humans. In this updated review, we discuss various nanodelivery systems that improve DNA vaccine technologies to enhance the immunological response against target diseases. We also provide possible perspectives on how we can bring this exciting vaccine technology to bedside applications. View Full-Text
Keywords: vaccine; nanoparticle; nanotechnology; adjuvant; immune cell targeting; peptide vaccine; DNA vaccine vaccine; nanoparticle; nanotechnology; adjuvant; immune cell targeting; peptide vaccine; DNA vaccine
Show Figures

Graphical abstract

MDPI and ACS Style

Lim, M.; Badruddoza, A.Z.M.; Firdous, J.; Azad, M.; Mannan, A.; Al-Hilal, T.A.; Cho, C.-S.; Islam, M.A. Engineered Nanodelivery Systems to Improve DNA Vaccine Technologies. Pharmaceutics 2020, 12, 30.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop